The primary therapeutic indications for these drugs include hypercholesterolemia, coronary artery disease, myocardial infarction, and hyperlipidaemia—conditions collectively classified under cardiovascular diseases—all of which target and inhibit PCSK9 activity. The gene discussed is PCSK9; the disease is cardiovascular disorder.